A/Prof Elizabeth Hinde
Jacob Haimson & Beverly Mecklenburg Lectureship
School of Physics
88 Scholarly works
22 Projects
HIGHLIGHTS
2026
Journal article
Wavelength and Polarization Multiplexed Nonlocal Metasurface for Quantitative Phase Microscopy
DOI: 10.1002/nap2.701902026
Journal article
Spatial triple-correlation spectroscopy reveals heterotrimer dynamics in live cells
DOI: 10.1016/j.bpj.2026.03.0072026
Journal article
Bringing the ends together: Cryo-EM structures of mycobacterial Ku in complex with DNA define its role in NHEJ synapsis
DOI: 10.1093/nar/gkaf14182025
Journal article
Adherent cells sustain membrane tension gradients independently of migration
DOI: 10.1038/s41467-025-65571-92023
Research grants (ARC, NHMRC, MRFF)
ARC Centre of Excellence in Quantum Biotechnology
2023
Research grants (other domestic)
ARC Centre of Excellence in Quantum Biotechnology
2020
Research Grant
Live Cell Super Resolution Imaging Facility
RECENT SCHOLARLY WORKS
2025
Journal article
MORC2 is a phosphorylation-dependent DNA compaction machine
DOI: 10.1038/s41467-025-60751-z2025
Journal article
Proximity proteomics reveals a mechanism of fatty acid transfer at lipid droplet-mitochondria- endoplasmic reticulum contact sites
DOI: 10.1038/s41467-025-57405-52025
Journal article
HSD17β11 regulates PLIN5-ATGL mediated lipolysis, but not hepatic lipid metabolism in mice
DOI: 10.1016/j.jlr.2025.1009432025
Journal article
Hippo signaling regulates the nuclear behavior and DNA binding times of YAP and TEAD to control transcription
DOI: 10.1126/sciadv.adw49742025
Journal article
Illuminating the dark: PEGylated carboxylated graphene quantum dots and curcumin in nucleolar activity and PDT-induced DNA damage in cancer
DOI: 10.1016/j.biopha.2025.1180962025
Journal article
Pair correlation microscopy of intracellular molecular transport
DOI: 10.1038/s41596-024-01097-6
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Breaking the Monopoly: A Parallel Route for mRNA Export
2026
Research grants (other domestic)
Uncovering the Mechanisms Driving Tumour Resistance to PARP Inhibitors